Concord Biotech Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '24 Sep 30, 2024	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020
Revenue	10,857	10,169	8,532	7,129	6,169	5,123
Revenue Growth (YoY)	11.88%	19.20%	19.67%	15.56%	20.42%	-
Cost of Revenue	2,761	2,448	1,921	1,719	1,169	1,381
Gross Profit	8,096	7,722	6,611	5,410	5,000	3,742
Selling, General & Admin	1,300	1,231	1,103	956.96	694.73	622.46
Other Operating Expenses	2,127	2,087	1,969	1,662	1,001	965.85
Operating Expenses	3,964	3,854	3,612	3,120	1,976	1,803
Operating Income	4,132	3,868	2,999	2,290	3,024	1,940
Interest Expense	-12.95	-25.52	-45.1	-54.84	-6.66	-6.99
Interest & Investment Income	30.41	30.41	44.41	47.87	17.87	0.76
Earnings From Equity Investments	-7.82	33.71	19.59	-36.38	-4.49	1.5
Currency Exchange Gain (Loss)	64.81	64.81	102.22	63.59	15.51	73.57
Other Non Operating Income (Expenses)	67.93	12.41	57.93	9.73	11.25	2.85
EBT Excluding Unusual Items	4,275	3,983	3,178	2,320	3,057	2,012
Gain (Loss) on Sale of Investments	140.65	140.65	37.17	52.3	69.86	124.16
Gain (Loss) on Sale of Assets	0.12	0.12	-0.94	-0.34	-	0.52
Other Unusual Items	-	-	-0.31	-	-	-
Pretax Income	4,417	4,126	3,220	2,375	3,127	2,136
Income Tax Expense	1,138	1,045	819.28	625.89	778.33	445.26
Net Income	3,279	3,081	2,401	1,749	2,349	1,691
Net Income to Common	3,279	3,081	2,401	1,749	2,349	1,691
Net Income Growth	7.74%	28.33%	37.25%	-25.53%	38.89%	-
Shares Outstanding (Basic)	105	105	105	105	105	105
Shares Outstanding (Diluted)	105	105	105	105	105	105
Shares Change (YoY)	-0.05%	-	-	-	-	-
EPS (Basic)	31.35	29.45	22.95	16.72	22.45	16.16
EPS (Diluted)	31.35	29.45	22.95	16.72	22.45	16.16
EPS Growth	7.79%	28.33%	37.25%	-25.52%	38.88%	-
Free Cash Flow	1,939	1,798	1,009	526.36	-373.59	-6.23
Free Cash Flow Per Share	18.54	17.18	9.65	5.03	-3.57	-0.06
Dividend Per Share	-	8.750	6.830	5.120	6.741	4.114
Dividend Growth	-	28.11%	33.40%	-24.05%	63.87%	-
Gross Margin	74.57%	75.93%	77.49%	75.89%	81.05%	73.05%
Operating Margin	38.06%	38.03%	35.15%	32.12%	49.01%	37.87%
Profit Margin	30.20%	30.30%	28.14%	24.54%	38.07%	33.01%
Free Cash Flow Margin	17.86%	17.68%	11.83%	7.38%	-6.06%	-0.12%
EBITDA	4,652	4,386	3,527	2,778	3,287	2,141
EBITDA Margin	42.85%	43.13%	41.33%	38.97%	53.28%	41.78%
D&A For EBITDA	520.08	518.51	527.85	487.98	263.27	200.53
EBIT	4,132	3,868	2,999	2,290	3,024	1,940
EBIT Margin	38.06%	38.03%	35.15%	32.12%	49.01%	37.87%
Effective Tax Rate	25.76%	25.32%	25.44%	26.35%	24.89%	20.84%
Revenue as Reported	11,251	10,507	8,885	7,364	6,308	5,436

Source: S&P Capital IQ. Standard template. Financial Sources.